Anti-inflammatory activity of clove ( Eugenia caryophyllata ) essential oil in human dermal fibroblasts
Open Access
- 1 January 2017
- journal article
- research article
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 55 (1) , 1619-1622
Abstract
Context: Clove (Eugenia caryophyllata Thunb. [Myrtaceae]) essential oil (CEO) has been shown to possess antimicrobial, antifungal, antiviral, antioxidant, anti-inflammatory and anticancer properties. However, few studies have focused on its topical use. Objective: We investigated the biological activity of a commercially available CEO in a human skin disease model. Materials and methods: We evaluated the effect of CEO on 17 protein biomarkers that play critical roles in inflammation and tissue remodelling in a validated human dermal fibroblast system, which was designed to model chronic inflammation and fibrosis. Four concentrations of CEO (0.011, 0.0037, 0.0012, and 0.00041%, v/v) were studied. The effect of 0.011% CEO on genome-wide gene expression was also evaluated. Results and discussion: CEO at a concentration of 0.011% showed robust antiproliferative effects on human dermal fibroblasts. It significantly inhibited the increased production of several proinflammatory biomarkers such as vascular cell adhesion molecule-1 (VCAM-1), interferon γ-induced protein 10 (IP-10), interferon-inducible T-cell α chemoattractant (I-TAC), and monokine induced by γ interferon (MIG). CEO also significantly inhibited tissue remodelling protein molecules, namely, collagen-I, collagen-III, macrophage colony-stimulating factor (M-CSF), and tissue inhibitor of metalloproteinase 2 (TIMP-2). Furthermore, it significantly modulated global gene expression and altered signalling pathways critical for inflammation, tissue remodelling, and cancer signalling processes. CEO significantly inhibited VCAM-1 and collagen III at both protein and gene expression levels. Conclusions: This study provides important evidence of CEO-induced anti-inflammatory and tissue remodelling activity in human dermal fibroblasts. This study also supports the anticancer properties of CEO and its major active component eugenol.Keywords
Funding Information
- dōTERRA
- DOTERRA INTERNATIONAL
This publication has 16 references indexed in Scilit:
- Anticancer potential of Syzygium aromaticum L. in MCF-7 human breast cancer cell linesPharmacognosy Research, 2014
- A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiationNature Chemical Biology, 2012
- Clove and eugenol in noncytotoxic concentrations exert immunomodulatory/anti-inflammatory action on cytokine production by murine macrophagesJournal of Pharmacy and Pharmacology, 2012
- Chemical target and pathway toxicity mechanisms defined in primary human cell systemsJournal of Pharmacological and Toxicological Methods, 2010
- A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression dataNucleic Acids Research, 2009
- In vitroandin vivoeffects of clove on pro-inflammatory cytokines production by macrophagesNatural Product Research, 2009
- beadarray: R classes and methods for Illumina bead-based dataBioinformatics, 2007
- Eugenol isolated from the essential oil of Eugenia caryophyllata induces a reactive oxygen species-mediated apoptosis in HL-60 human promyelocytic leukemia cellsCancer Letters, 2005
- Rapid Structure-Activity and Selectivity Analysis of Kinase Inhibitors by BioMAP Analysis in Complex Human Primary Cell-Based ModelsASSAY and Drug Development Technologies, 2004
- An integrative biology approach for analysis of drug action in models of human vascular inflammationThe FASEB Journal, 2004